Abstract:Metastatic malignant melanoma is the deadliest skin cancer, and it is characterised by its high resistance to apoptosis. The main melanoma driving mutations are part of ERK pathway, with BRAF mutations being the most frequent ones, followed by NRAS, NF1 and MEK mutations. Increasing evidence shows that the MST2/Hippo pathway is also deregulated in melanoma. While mutations are rare, MST2/Hippo pathway core proteins expression levels are often dysregulated in melanoma. The expression of the tumour suppressor RASSF1A, a bona fide activator of the MST2 pathway, is silenced by promoter methylation in over half of melanomas and correlates with poor prognosis. Here, using mass spectrometry-based interaction proteomics we identified the Second Mitochondria-derived Activator of Caspases (SMAC) as a novel LATS1 interactor. We show that RASSF1A-dependent activation of the MST2 pathway promotes LATS1-SMAC interaction and negatively regulates the antiapoptotic signal mediated by the members of the IAP family. Moreover, proteomic experiments identified a common cluster of apoptotic regulators that bind to SMAC and LATS1. Mechanistic analysis shows that the LATS1-SMAC complex promotes XIAP ubiquitination and its subsequent degradation which ultimately results in apoptosis. Importantly, we show that the oncogenic BRAF V600E mutant prevents the proapoptotic signal mediated by the LATS1-SMAC complex while treatment of melanoma cell lines with BRAF inhibitors promotes the formation of this complex, indicating that inhibition of the LATS1-SMAC might be necessary for BRAF V600E -driven melanoma. Finally, we show that LATS1-SMAC interaction is regulated by the SMAC mimetic Birinapant, which requires C-IAP1 inhibition and the degradation of XIAP, suggesting that the MST2 pathway is part of the mechanism of action of Birinapant. Overall, the current work shows that SMAC-dependent apoptosis is regulated by the LATS1 tumour suppressor and supports the idea that LATS1 is a signalling hub that regulates the crosstalk between the MST2 pathway, the apoptotic network and the ERK pathway.

Putative Tumor Suppressor Lats2 Induces Apoptosis Through Downregulation of Bcl-2 and Bcl-x(L).

LATS1 tumor suppressor regulates G2/M transition and apoptosis

Lats2, a Putative Tumor Suppressor, Inhibits G1/S Transition

Erratum: LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction (2013) 5(6) (1650–1663), (S2211124713007213), (10.1016/j.celrep.2013.11.037))

LATS2 promotes cardiomyocyte H9C2 cells apoptosis via the Prx3-Mfn2-mitophagy pathways

Cell type-dependent function of LATS1/2 in cancer cell growth

Promoter Hypermethylation-Mediated Down-Regulation of LATS1 and LATS2 in Human Astrocytoma

Tpd52l2 Silencing Inhibits Lung Cancer Cell Proliferation By Cell Cycle G2/M Phase Arrest

Overexpression of A Novel Tumor Metastasis Suppressor Gene Tmsg1/Lass2 Induces Apoptosis Via A Caspase-Dependent Mitochondrial Pathway

Human Homologue of the Drosophila Melanogaster Lats Tumour Suppressor Modulates CDC2 Activity.

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

T851I Mutation of Human Large Tumor Suppressor 1 Disrupts Its Kinase Activity and Tumor-Suppressor Functions.

Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma

LCAT1 is an Oncogenic LncRNA by Stabilizing the IGF2BP2-CDC6 Axis

Pathological significance and prognostic role of LATS2 in prostate cancer

Interaction of LATS1 with SMAC links the MST2/Hippo pathway with apoptosis in an IAP-dependent manner

Identification of Las2, a Major Modifier Gene Affecting the Pas1 Mouse Lung Tumor Susceptibility Locus.

Pig large tumor suppressor 2 (Lats2), a novel gene that may regulate the fat reduction in adipocyte.

Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas